The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease
Open accessAbstract
Synaptic dysfunction occurs early in senile dementias, presumably as a result of decreased levels of functional synaptic proteins as found in autopsied brains of patients with Alzheimer's disease (AD) or frontotemporal dementia (FTD). Plasma neuronal‐derived exosomes (NDEs) were recovered by precipitation and immunoabsorption from 12 patients with AD, 16 with FTD, and 28 controls in a cross‐sectional study, and from 9 patients with AD, 10with FTD, and 19 controls in a longitudinal study. Six synaptic proteins in NDE extracts were quantified by ELISAs and normalized for exosome amounts. NDE levels of synaptophysin, synaptopodin, synaptotagmin‐2, and neurogranin were significantly lower in patients with FTD and ADthan in controls, but those of growth‐associated protein 43 and synapsin 1 were reduced only in patients with AD. Functionally relevant phosphorylation of synapsin 1 serine 9 was reduced in patients with FTD and AD, although total synapsin 1 protein was higher in FTD than in controls. NDE levels of synaptotagmin, synaptophysin, and neurograninwere decreased yearsbeforedementia inpatientswithFTD and AD.NDElevelsof synaptopodin, synaptotagmin, and synaptophysin, but not of amyloid β‐peptide 42 or P‐T181‐tau, were correlated significantly with cognition assessed bymini‐mental state examination or AD assessment scale‐cognitive subscale. NDE synaptic proteins may be useful preclinical indices and progression measures in senile dementias.—Goetzl, E. J., Kapogiannis, D., Schwartz, J. B., Lobach, I. V., Goetzl, L., Abner, E. L., Jicha, G. A., Karydas, A.M., Boxer, A., Miller, B. L. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. FASEB J. 30, 4141–4148 (2016). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ng is a postsynaptic protein that is important for maintaining synaptic plasticity and regulating calcium ion influxes, while SNAP25 is a presynaptic protein that plays a crucial role in synaptic vesicle fusion and neurotransmitter release, and both these proteins have been shown to play a key role in AD disease pathophysiology, although they may be less clinically relevant for FTD [10,[45][46][47”
In the citing paper
“Ng is a postsynaptic protein that is important for maintaining synaptic plasticity and regulating calcium ion influxes, while SNAP25 is a presynaptic protein that plays a crucial role in synaptic vesicle fusion and neurotransmitter release, and both these proteins have been shown to play a key role in AD disease pathophysiology, although they may be less clinically relevant for FTD [10,[45][46][47”
In the citing paper
“Ng is a postsynaptic protein that is important for maintaining synaptic plasticity and regulating calcium ion influxes, while SNAP25 is a presynaptic protein that plays a crucial role in synaptic vesicle fusion and neurotransmitter release, and both these proteins have been shown to play a key role in AD disease pathophysiology, although they may be less clinically relevant for FTD [10,[45][46][47”
In the citing paper
“there is a significant reduction of plasma neuronal-derived exosomal neurogranin in AD patients compared with the healthy controls.549”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [549]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationAppelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Südhof, T. C. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131412 · Cited by 2,547
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Qualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., van Swieten, J. C., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,046
Normal development of brain circuits
Tau, G. Z., & Peterson, B. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.115 · Cited by 1,391
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Self-citationAltered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease
Goetzl, E. J., Boxer, A., Schwartz, J. B., Abner, E. L., Petersen, R. C., Miller, B. L., & Kapogiannis, D. (2015) · Neurology · doi:10.1212/wnl.0000000000001702 · Cited by 446
Self-citationDifferential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunction
Reddy, P. H., Mani, G., Park, B. S., Jacques, J., Murdoch, G., Whetsell, W., Kaye, J., & Manczak, M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7203 · Cited by 372
The calcium sensor synaptotagmin 7 is required for synaptic facilitation
Jackman, S. L., Turecek, J., Belinsky, J. E., & Regehr, W. G. (2016) · Nature · doi:10.1038/nature16507 · Cited by 346
Synaptophysin: leading actor or walk‐on role in synaptic vesicle exocytosis?
Valtorta, F., Pennuto, M., Bonanomi, D., & Benfenati, F. (2004) · BioEssays · doi:10.1002/bies.20012 · Cited by 345
Kapogiannis, D., Boxer, A., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U., Frassetto, L., Petersen, R. C., Miller, B. L., & Goetzl, E. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262048 · Cited by 345
Self-citationKvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 340
Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease.
Masliah, E., Terry, R. D., Alford, M. F., DeTeresa, R. M., & Hansen, L. A. (1991) · PubMed · Cited by 328
Short-term synaptic plasticity is altered in mice lacking synapsin I
Rosahl, T. (1993) · Cell · doi:10.1016/0092-8674(93)90487-b · Cited by 328
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Kester, M. I., Teunissen, C. E., Crimmins, D. L., Herries, E. M., Ladenson, J. H., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1867 · Cited by 246
Low neural exosomal levels of cellular survival factors in Alzheimer's disease
Goetzl, E. J., Boxer, A., Schwartz, J. B., Abner, E. L., Petersen, R. C., Miller, B. L., Carlson, O. D., Mustapic, M., & Kapogiannis, D. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.211 · Cited by 208
Self-citationCano, S. J., Posner, H. B., Moline, M. L., Hurt, S. W., Swartz, J., Hsu, T., & Hobart, J. C. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.204008 · Cited by 208
Neurochemical Dissection of Synaptic Pathology in Alzheimer's Disease
Davidsson, P., & Blennow, K. (1998) · International Psychogeriatrics · doi:10.1017/s1041610298005110 · Cited by 182
Miyakawa, T., Yared, E., Pak, J. H., Huang, F. L., Huang, K., & Crawley, J. N. (2001) · Hippocampus · doi:10.1002/hipo.1092 · Cited by 178
Clare, R., King, V. G., Wirenfeldt, M., & Vinters, H. V. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22392 · Cited by 163
Guekht, A. B., Skoog, I. G., Korczyn, A. D., Zakharov, V. V., Eeg, M., & Vigonius, U. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000357122 · Cited by 114
Bacaj, T., Wu, D., Burré, J., Malenka, R. C., Liu, X., & Südhof, T. C. (2015) · PLoS Biology · doi:10.1371/journal.pbio.1002267 · Cited by 96
Identification of a human synaptotagmin-1 mutation that perturbs synaptic vesicle cycling.
Baker, K., Gordon, S. L., Grozeva, D., van Kogelenberg, M., Roberts, N. Y., Pike, M. G., Blair, E., Hurles, M., Chong, W., Baldeweg, T., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79765 · Cited by 94
Brain development: anatomy, connectivity, adaptive plasticity, and toxicity
Kalia, M. (2008) · Metabolism · doi:10.1016/j.metabol.2008.07.009 · Cited by 86
Physiological and Pathophysiological Implications of Synaptic Tau
Regan, P. L., Whitcomb, D. J., & Cho, K. (2016) · The Neuroscientist · doi:10.1177/1073858416633439 · Cited by 83
Ca2+-dependent Formation of a Dynamin-Synaptophysin Complex
Daly, C., & Ziff, E. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110815200 · Cited by 73
Ca2+-dependent interaction of the growth-associated protein GAP-43 with the synaptic core complex
HARUTA, T., Takami, N., OHMURA, M., Misumi, Y., & Ikehara, Y. (1997) · Biochemical Journal · doi:10.1042/bj3250455 · Cited by 61
Synaptotagmins in Neurodegeneration
Glavan, G., Schliebs, R., & Živin, M. (2009) · The Anatomical Record · doi:10.1002/ar.21026 · Cited by 58
Gordon, S. L., & Cousin, M. A. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0636-13.2013 · Cited by 51
Reduced in vitro phosphorylation of synapsin I (site 1) in Alzheimer's disease postmortem tissues.
Parks, K., Sugár, J., Haroutunian, V., Bierer, L., Perl, D. P., & Wallace, W. (1991) · Brain Research. Molecular Brain Research · doi:10.1016/0169-328x(91)90137-m · Cited by 39
Irizarry, M. C., Webb, D. J., Bains, C., Barrett, S. J., Lai, R. Y. K., Laroche, J. P., Hosford, D. A., Maher‐Edwards, G., & Weil, J. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14304 · Cited by 30
Cited by
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“In contrast, there is a significant reduction of plasma neuronal-derived exosomal neurogranin in AD patients compared with the healthy controls.(549) More importantly, the CSF neurogranin increases exclusively in AD patients and has not been observed in other neurodegenerative disorders, such as frontotemporal dementi…”
ResultCurrent state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Targeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles
Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., & Karamanos, Y. (2020) · Cells · doi:10.3390/cells9040851 · Cited by 503
Crosstalk Between Astrocytes and Microglia: An Overview
Matejuk, A., & Ransohoff, R. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01416 · Cited by 445
Mustapic, M., Eitan, E., Werner, J. K., Berkowitz, S. T., Lazaropoulos, M. P., Tran, J., Goetzl, E. J., & Kapogiannis, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00278 · Cited by 441
Self-citation
Metadata
- Authors
- Goetzl, E. J., Kapogiannis, D., Schwartz, J. B., Lobach, I. V., Goetzl, L., Abner, E. L., Jicha, G. A., Karydas, A. M., Boxer, A., & Miller, B. L.
- Affiliations
- University of California, San Francisco (US)
- National Institute on Aging (US)
- Temple University (US)
- University of Kentucky (US)
- Corresponding author
- Goetzl, Edward J.
- ORCID
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2016-09-06
- Volume
- 30
- Issue
- 12
- Pages
- 4141-4148
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC5102122
- OpenAlex
- W2511373877
- Cited by
- 398
- References
- 40
- Citations by year
- 2026: 24 · 2025: 39 · 2024: 48 · 2023: 46 · 2022: 49 · 2021: 51 · 2020: 54 · 2019: 43 · 2018: 27 · 2017: 17
- FWCI
- 23.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The FASEB Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Alzheimer's Association
- Alzheimer’s Research UK
- Weston Brain Institute
- National Institutes of Health
- National Institute on Aging (P30 AG028383)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- synaptic proteins, frontotemporal dementia, Alzheimer's disease, synaptophysin, synaptopodin, synaptotagmin 2, neurogranin, synapsin-1, growth-associated protein 43, plasma biomarkers, preclinical dementia, cognitive decline, synaptic dysfunction
- MeSH terms
- Alzheimer Disease, Cognition, Cross-Sectional Studies, Humans, Longitudinal Studies, Synapses, Biomarkers, Amyloid beta-Peptides, tau Proteins, Exosomes, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.